Swipe Left For English News
1
公司位列标普全球企业可持续发展评估（CSA）前1%
2
公司连续三年入选标普全球《可持续发展年鉴》
3
引领绿色生物药发展，技术创新赋能健康未来
上海,
2025年3月11日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，凭借2024年在可持续发展领域的卓越表现，公司入选标普全球（S&P Global）《可持续发展年鉴2025》（以下简称“年鉴”），并在标普全球企业可持续发展评估（CSA）中位列行业前茅，跻身全球前1%。这是药明生物连续第三年获此殊荣。
该《年鉴》基于标普全球CSA，评选出各行业在可持续发展方面表现优异的企业。在2024年CSA评估的7690家企业中，仅有来自62个行业的780家企业脱颖而出，成功入选该《年鉴》。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸能够再次入选《年鉴》，这不仅是对我们在可持续发展领域卓越表现的认可，更是对我们坚定践行可持续发展承诺的充分肯定。作为绿色生物药解决方案领域的全球领导者，我们始终追求ESG卓越表现，并赋能全球合作伙伴，助力其迈向ESG发展新高度。未来，我们将继续携手各方，共同推动整个价值链的可持续发展。
近年来，药明生物凭借在可持续发展领域的持续努力和显著成就，入选2023年和2024年道琼斯可持续发展指数（DJSI）。此外，作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司连续两年获得明晟（MSCI）最高AAA ESG评级和EcoVadis“铂金”评级；凭借领先的绿色生物药解决方案（Green CRDMO），公司成功入选UNGC “‘二十年二十佳’企业可持续发展案例”报告；连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
1
Ranking in top 1% of S&P Global CSA Score
2
Inclusion in Global Yearbook for third consecutive year
3
Leader in Green CRDMO to drive innovation for a healthier future
Shanghai,
March 11, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability Yearbook 2025 ("Yearbook") for its strong sustainability performance in 2024. The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level of recognition.
The Yearbook aims to distinguish individual companies — within a range of industries — that have demonstrated strong corporate sustainability, based on their S&P Global 2024 CSA Score. Out of the 7,690 companies assessed in the 2024 CSA, only 780 companies, across 62 industries, were recognized as the top performers and selected for inclusion in Yearbook 2025.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.
In the past couple of years, WuXi Biologics has also been named to the 2023 and 2024 Dow Jones Sustainability Indices (DJSI) for its unremitting efforts and notable achievements in promoting sustainable development. In addition, as a participant of United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating and EcoVadis Platinum Medal for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
2025-06-15
26页
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论